UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024)

The global litigation saga involving Amgen’s PCSK9 antibodies has long served as a high-stakes test case for jurisdictional approaches to broad, functionally defined antibody claims. Following the US Supreme Court’s landmark finding of lack of enablement in Amgen v Sanofi (IPKat), and the UPC Munich Central Division’s initial revocation of the equivalent European patent (IPKat), all eyes